Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Kifle, Bruck (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08008318
ABSTRACT:
The present invention relates to 39-desmethoxyrapamycin derivatives and their uses thereof. The present invention provides for the use of these compounds in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4596556 (1986-06-01), Morrow et al.
patent: 4790824 (1988-12-01), Morrow et al.
patent: 4941880 (1990-07-01), Burns
patent: 5023262 (1991-06-01), Caufield et al.
patent: 5064413 (1991-11-01), McKinnon et al.
patent: 5138051 (1992-08-01), Hughes et al.
patent: 5206018 (1993-04-01), Sehgal et al.
patent: 5221670 (1993-06-01), Caufield
patent: 5312335 (1994-05-01), McKinnon et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5378836 (1995-01-01), Kao et al.
patent: 5383851 (1995-01-01), McKinnon, Jr. et al.
patent: 5391730 (1995-02-01), Skotnicki et al.
patent: 5399163 (1995-03-01), Peterson et al.
patent: 5432183 (1995-07-01), Schulte
patent: 5446048 (1995-08-01), Failli et al.
patent: 5563145 (1996-10-01), Failli et al.
patent: 5665772 (1997-09-01), Cottens et al.
patent: 5708002 (1998-01-01), Luly et al.
patent: 5712129 (1998-01-01), Ford
patent: 5728710 (1998-03-01), Luengo
patent: 5912253 (1999-06-01), Cottens et al.
patent: 5955457 (1999-09-01), Lee et al.
patent: 6015815 (2000-01-01), Mollison
patent: 6485514 (2002-11-01), Wrenn, Jr.
patent: 7183289 (2007-02-01), Zhang et al.
patent: 2003/0176915 (2003-09-01), Wright et al.
patent: 2004/0147541 (2004-07-01), Lane et al.
patent: 2005/0032825 (2005-02-01), Metcalf, III et al.
patent: 0663916 (1995-07-01), None
patent: 93/16189 (1993-08-01), None
patent: 9409010 (1994-04-01), None
patent: 9641807 (1996-12-01), None
patent: 98/02441 (1998-01-01), None
patent: 9804279 (1998-02-01), None
patent: 0103692 (2001-01-01), None
patent: 0181355 (2001-11-01), None
patent: 0187263 (2001-11-01), None
patent: 2004/007709 (2004-01-01), None
patent: 2004007709 (2004-01-01), None
patent: 2004101583 (2004-11-01), None
patent: 2006/016167 (2006-02-01), None
patent: 2006/095173 (2006-09-01), None
Paiva, N. L., et al. “Incorporation of Acetate, Propionate, and Methionine Into Rapamcyin by Streptomyces Hygroscopicus.” Journal of Natural Products, 54(1): 167-177 (Jan.-Feb. 1991).
Paiva, N. L., et al. “The immediate precursor of the nitrogen-containing ring of rapamycin in free pipecolic acid.” Enzyme Microb, Technol. 15: 581-585 (Jul. 1993).
Perin, E. C. “Choosing a Drug-Eluting Stent A Comparison Between CYPHER and TAXUS.” Reviews in Cardiovascular Medicine, 6 (suppl 1): S13-521 (2005).
Persidis, A. “Cancer multidrug resistance.” Nature Biotechnology, 17: 94-95 (Jan. 1999).
Powell, N., et al. “The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients.” Allergy Clin. Immunol., 108(6): 915-917 (2001).
Rabinovitch, A., et al. “Combination Therapy With Sirolimus and Interleukin-2 Prevents Spontaneous and Recurrent Autoimmune Diabetes in NOD Mice.” Diabetes, 51: 638-345 (Mar. 2002).
Raught, B., et al. “The target of rapamycin (TOR) proteins.” Proc. Natl. Acad. Sci. USA, 98(13): 7037-7044 (Jun. 19, 2001).
Reather, J. A. “Late steps in the biosynthesis of macrocyclic lactones.” Ph.D. Dissertation, University of Cambridge (Apr. 2000).
Reitamo, S., et al. “Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.” British Journal of Dermatology, 145: 438-445 (2001).
Roth, T., et al. “Human Tumor Cell Lines Demonstrating the Characteristics of Patient Tumors as useful Models for Anticancer Drug Screening.” In Feibig, H. H., et al. (ads), Relevance of Tumor Models for Anticancer Drug Development. Contrib. Oncol., 54: 145-156 (1999).
Roymans, D., et al. “Phosphatidylinositol 3-kinases in tumor progression,” European Journal of Biochemistry, 268: 487-498 (2001).
Schwecke, T., et al. “The biosynthetic gene duster for the polyketide immunosuppressant rapamycin.” Proc. Natl. Acad. Sci. USA, 92: 7839-71343 (Aug. 1995).
Sedrani, R., et al. “Chemical Modification of Rapamycin: The Discovery of SDZ RAD.” Transplantation Proceedings, 30: 2192-2194 (1998).
Sehgal, R., et al. “Rapamycin (AY-22,989), A New Antifungal Antibiotic: II. Fermentation, Isolation and Characterization.” Journal of Antibiotics, 38(10): 1975).
Shepherd, P. R., et al. “Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.” Biochemical Journal, 33: 471-490 (1999).
Steiner, U., et al. “Expression of Multidrug Resistance Genes MVP, MDR1, and MRP1 Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients.” Journal of Clinical Oncology, 20(15): 3282-3292 (Aug. 1, 2002).
Stein, J. P., et al. “Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.” Proc. Natl. Acad. Sal. USA, 94: 2019-2024 (Mar. 1997).
Szakacs, G., et al. “Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells.” Cancer Cell, 6: 129-137 (Aug. 2004).
Tanford, C. “Protein Denaturation.” Adv. Prot. Chem., 23: 121-282 (1968).
Tanford, C. “Protein Denaturation: Part C. Theoretical Models for the mechanism of denaturation.” Adv. Prot Chem., 24: 1-95 (1970).
Tang, S. J., et al. “A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus.” Proc. Natl. Acad. Sci. USA, 99(1): 467-472 (Jan. 8, 2002).
Tee, A. R., et al. “Caspase Cleavage of Initiation Factor 4E-Binding Protein 1 Yields a Dominant Inhibitor of Cap-Dependent Translation and Reveals a Novel Regulatory Motif.” Molecular and Cellular Biology, 22(6): 1674-1683 (Mar. 2002).
Toshima, K., et al. “Recent Progress in O-GlycosylatIon Methods and Its Application to Natural Products Synthesis.” Chemical Review, 93: 1503-1531 (1983).
Trepanier, D. J. et al. “Rapamycln: Distribution, Pharmacokinetics and Therapeutic Range Investigations: An Update.” Clinical Biochemistry, 31(5): 345-351 (1998).
Vezina, C. at al. “Rapamycin (AY-22,989), A New Antifungal Antibiotic: I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle.” Journal of Antibiotics, 28: 721-728 (1975).
Volpe, D. et al. “Towards Standardization of an In Vitro Method of Drug Absorption.” Pharmacopeial Forum, 27(4): 2916-2922 (Jul.-Aug. 2001).
Waller, J. R., et al. “Molecular mechanism and renal allograft fibrosis.” British Journal of Surgery, 88: 1429-1441 (2001).
Warner, L. M., et al. “A Modification of the in Vivo Mixed Lymphocyte Reaction and Rapamycin's Effect in This Model.” Clinical Immunology and Immunopathology, 34(3): 242-247 (Sep. 1992).
Yu, K., et al. “mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.” Endocrine-Related Cancer, 8: 249-258 (2001).
Zhu, J., et al. “Rapamycin Inhibits Hepatic Stellate Cell Proliferation in Vitro and Limits Fibrogenesis in an In Vivo Model of Liver Fibrosis.” Gastroenterology: 117: 1198-1204 (1999).
March, J. March's Adv
Beckmann Christoph Hendrik
Moss Steven James
Sheridan Rose Mary
Wilkinson Barrie
Zhang Mingqiang
Biotica Technology Limited
Dann Dorfman Herrell & Skillman
Kifle Bruck
Netter, Jr. Robert C.
LandOfFree
39-desmethoxy derivatives of rapamycin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 39-desmethoxy derivatives of rapamycin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 39-desmethoxy derivatives of rapamycin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2771134